However, recent clinical screens found that amplification and/or activating mutations in the gene encoding KRAS decoupled the RAS-MAPK pathway activity from the MET receptor, constituting the most common form of resistance against MET-targeted therapies in METΔex14-presenting tumours [23,24,25]. Here, KRAS is linked to neoplasm.